Full Text Journal Articles by
Author Robert Didomenico

Advertisement

Find full text journal articles






Influence of digoxin on mortality in patients with atrial fibrillation: Overview of systematic reviews.

William L Baker, Diana M Sobieraj, Robert J DiDomenico,

Once a routine part of atrial fibrillation (AF) management, digoxin use has declined. Likely hastening this decline are findings from several studies and systematic reviews identifying a potential association between digoxin use and all-cause mortality in AF populations. However, inconsistency exists within some of these studies potentially leading to confusion ... Read more >>

Pharmacotherapy (Pharmacotherapy)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Comparison of Cardiac Events Associated With Azithromycin vs Amoxicillin.

Haridarshan Patel, Gregory S Calip, Robert J DiDomenico, Glen T Schumock, Katie J Suda, Todd A Lee,

<h4>Importance</h4>Conflicting evidence exists on the association between azithromycin use and cardiac events.<h4>Objective</h4>To compare the odds of cardiac events among new users of azithromycin relative to new users of amoxicillin using real-world data.<h4>Design, setting, and participants</h4>This retrospective cohort study used data from Truven Health Analytics MarketScan database from January 1, 2009, ... Read more >>

JAMA Netw Open (JAMA network open)
[2020, 3(9):e2016864]

Cited: 0 times

View full text PDF listing >>



Advertisement

Risk of cardiac events with azithromycin-A prediction model.

Haridarshan Patel, Robert J DiDomenico, Katie J Suda, Glen T Schumock, Gregory S Calip, Todd A Lee,

Previous studies have suggested an increased risk of cardiac events with azithromycin, but the predictors of such events are unknown. We sought to develop and validate two prediction models to identify such predictors. We used data from Truven Marketscan Database (01/2009 to 06/2015). Using a split-sample approach, we developed two ... Read more >>

PLoS One (PloS one)
[2020, 15(10):e0240379]

Cited: 0 times

View full text PDF listing >>



Beyond Heart Failure and Ischemic Heart Disease: A Scoping Review of Novel Uses of Ivabradine in Adults.

Erika L Hellenbart, Tina Griffin, Robert J DiDomenico,

Ivabradine lowers heart rate by inhibiting the hyperpolarization-activated current in pacemaker cells, and its use for the treatment of heart failure (HF) and ischemic heart disease (IHD) is well described. Ivabradine may be an attractive treatment option for other conditions for which a reduction in heart rate is desirable but ... Read more >>

Pharmacotherapy (Pharmacotherapy)
[2020, 40(6):544-564]

Cited: 0 times

View full text PDF listing >>



Prevalence of Cardiac Risk Factors in Patients Prescribed Azithromycin before and after the 2012 FDA Warning on the Risk of Potentially Fatal Heart Rhythms.

Haridarshan Patel, Gregory Sampang Calip, Robert J DiDomenico, Glen T Schumock, Katie J Suda, Todd A Lee,

<h4>Study objective</h4>To measure the prevalence of cardiac risk factors among patients prescribed azithromycin before and after the United States Food and Drug Administration (FDA) issued a warning on May 17, 2012, on the risk of potentially fatal heart rhythms associated with the drug.<h4>Design</h4>Retrospective cohort study using administrative claims data.<h4>Data source</h4>Truven ... Read more >>

Pharmacotherapy (Pharmacotherapy)
[2020, 40(2):107-115]

Cited: 3 times

View full text PDF listing >>



Cost-Effectiveness of Strategies to Personalize the Selection of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome.

Kibum Kim, Daniel R Touchette, Larisa H Cavallari, Amer K Ardati, Robert J DiDomenico,

<h4>Purpose</h4>Perform a cost-effectiveness analysis comparing strategies for selecting P2Y<sub>12</sub> inhibitors in acute coronary syndrome (ACS).<h4>Methods</h4>Six strategies for selection of P2Y<sub>12</sub> inhibitors in ACS were compared from the US healthcare system perspective: (1) clopidogrel for all (universal clopidogrel); (2) ticagrelor guided by platelet reactivity assay (PRA; clopidogrel + phenotype); (3) ticagrelor ... Read more >>

Cardiovasc Drugs Ther (Cardiovascular drugs and therapy)
[2019, 33(5):533-546]

Cited: 1 time

View full text PDF listing >>



Design of the patient navigator to Reduce Readmissions (PArTNER) study: A pragmatic clinical effectiveness trial.

Valentin Prieto-Centurion, Sanjib Basu, Nina Bracken, Elizabeth Calhoun, Carolyn Dickens, Robert J DiDomenico, Richard Gallardo, Victor Gordeuk, Melissa Gutierrez-Kapheim, Lewis L Hsu, Sai Illendula, Min Joo, Uzma Kazmi, Amelia Mutso, A Simon Pickard, Barry Pittendrigh, Jamie L Sullivan, Mark Williams, Jerry A Krishnan,

Previous work indicates the potential for community health workers and peer coaches serving as patient navigators to improve processes of care and health outcomes during care transitions, but have not been sufficiently tested to determine if such programs improve measures of patient experience in minority serving institutions. The objectives of ... Read more >>

Contemp Clin Trials Commun (Contemporary clinical trials communications)
[2019, 15:100420]

Cited: 1 time

View full text PDF listing >>



Survey of Anticoagulation Practices with the Impella Percutaneous Ventricular Assist Device at High-Volume Centers.

Brent N Reed, Robert J DiDomenico, J Erin Allender, James C Coons, Jenna F Cox, Daniel Johnson, Carrie S Oliphant, Douglas L Jennings,

Objectives:To characterize anticoagulation practices with the Impella percutaneous ventricular assist device (pVAD). Background:Managing anticoagulation in patients being supported by the Impella pVAD is made challenging by several unique features of the device. These include the release of a dextrose-based purge solution containing unfractionated heparin (UFH), the need to concurrently administer ... Read more >>

J Interv Cardiol (Journal of interventional cardiology)
[2019, 2019:3791307]

Cited: 0 times

View full text PDF listing >>



Frequency of "on-label" use of intravenous diltiazem for rate control in patients with acute-onset atrial fibrillation or atrial flutter.

Nicole M Gasbarro, Robert J DiDomenico,

Purpose:The study was designed to characterize "on-label" use of i.v. diltiazem in patients with acute atrial fibrillation or flutter (AFF). Methods:An IRB-approved, single-center, retrospective, observational design was used. Eligible patients had acute AFF with heart rate >120 bpm and received i.v. diltiazem from June 1, 2012, to June 30, 2014. ... Read more >>

Am J Health Syst Pharm (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists)
[2019, 76(4):214-220]

Cited: 0 times

View full text PDF listing >>



Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome.

Kibum Kim, Todd A Lee, Daniel R Touchette, Robert J DiDomenico, Amer K Ardati, Surrey M Walton,

<h4>Background</h4>In patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI), newer antiplatelet agents prasugrel and ticagrelor have lower rates of cardiovascular events when compared with clopidogrel. However, it is unclear whether there are differences in economic outcomes when comparing these agents in ACS-PCI patients.<h4>Objective</h4>To assess aggregated costs ... Read more >>

J Manag Care Spec Pharm (Journal of managed care & specialty pharmacy)
[2018, 24(8):800-812]

Cited: 0 times

View full text PDF listing >>



Need for a universal residency application deadline.

Robert J DiDomenico,

Am J Health Syst Pharm (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists)
[2018, 75(12):849-850]

Cited: 0 times

View full text PDF listing >>



Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States.

Patrick M Zueger, Varun M Kumar, Rachel L Harrington, Gianna C Rigoni, Alicia Atwood, Robert J DiDomenico, Daniel R Touchette,

OBJECTIVE:Sacubitril/valsartan (SAC/VAL) has been shown to reduce mortality and hospitalization in patients with heart failure with reduced ejection fraction (HFrEF) compared with enalapril but at a substantially higher cost. This study evaluates the cost-effectiveness of SAC/VAL versus enalapril in patients with HFrEF over a 5-year time horizon from the U.S. ... Read more >>

Pharmacotherapy (Pharmacotherapy)
[2018, 38(5):520-530]

Cited: 5 times

View full text PDF listing >>



Improving peer review: What authors can do.

William L Baker, Robert J DiDomenico, Stuart T Haines,

Am J Health Syst Pharm (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists)
[2017, 74(24):2076-2079]

Cited: 1 time

View full text PDF listing >>



Improving peer review: What journals can do.

Stuart T Haines, William L Baker, Robert J DiDomenico,

Am J Health Syst Pharm (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists)
[2017, 74(24):2086-2089]

Cited: 2 times

View full text PDF listing >>



Improving peer review: What reviewers can do.

Robert J DiDomenico, William L Baker, Stuart T Haines,

Am J Health Syst Pharm (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists)
[2017, 74(24):2080-2084]

Cited: 1 time

View full text PDF listing >>



Pharmacologic Considerations in the Management of Patients Receiving Left Ventricular Percutaneous Mechanical Circulatory Support.

J Erin Allender, Brent N Reed, Jenna L Foster, Jeremy D Moretz, Carrie S Oliphant, Douglas L Jennings, Robert J DiDomenico, James C Coons,

Percutaneous mechanical circulatory support (MCS) devices, including the intraaortic balloon pump, Impella, and TandemHeart, are often used for hemodynamic support in the setting of refractory cardiogenic shock. The thrombotic and bleeding complications associated with these devices is well recognized, and the Impella and TandemHeart devices have unique anticoagulation considerations that ... Read more >>

Pharmacotherapy (Pharmacotherapy)
[2017, 37(10):1272-1283]

Cited: 3 times

View full text PDF listing >>



Comparative Effectiveness of Oral Antiplatelet Agents in Patients with Acute Coronary Syndrome.

Kibum Kim, Todd A Lee, Amer K Ardati, Robert J DiDomenico, Daniel R Touchette, Surrey M Walton,

<h4>Objective</h4>In randomized controlled trials, prasugrel and ticagrelor reduced cardiovascular complications in patients with acute coronary syndrome (ACS) compared with clopidogrel. However, limited head-to-head comparisons have been conducted across the three antiplatelet agents using real-world data. The aim of this study was to compare clinical outcomes of three strategies during a ... Read more >>

Pharmacotherapy (Pharmacotherapy)
[2017, 37(8):877-887]

Cited: 3 times

View full text PDF listing >>



Should Digoxin Continue To Be Used for the Management of Atrial Fibrillation?

Can J Hosp Pharm (The Canadian journal of hospital pharmacy)
[2017, 70(5):391-394]

Cited: 0 times

View full text PDF listing >>



Letter--The Authors Respond.

Kibum Kim, Robert J DiDomenico, Daniel R Touchette, Surrey M Walton,

<h4>Disclosures</h4>None of the authors of this study are involved in financial or personal relationships with agencies, institutions, or organizations that inappropriately influenced the statistical analysis plan or interpretation of the study results. DiDomenico received an honorarium from Amgen for the preparation of a heart failure drug monograph for Pharmacy Practice ... Read more >>

J Manag Care Spec Pharm (Journal of managed care & specialty pharmacy)
[2017, 23(5):599-600]

Cited: 0 times

View full text PDF listing >>



Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome.

Kibum Kim, Todd A Lee, Daniel R Touchette, Robert J DiDomenico, Amer K Ardati, Surrey M Walton,

<h4>Background</h4>Recent trials demonstrated the efficacy of prasugrel and ticagrelor compared with clopidogrel in the reduction of cardiovascular complications in patients with acute coronary syndrome (ACS). However, it is unclear how use of the 3 antiplatelet medications has changed in commercially insured patients since the advent of the new agents.<h4>Objectives</h4>To (a) ... Read more >>

J Manag Care Spec Pharm (Journal of managed care & specialty pharmacy)
[2017, 23(1):57-63]

Cited: 10 times

View full text PDF listing >>



Interventions to reduce rehospitalizations after chronic obstructive pulmonary disease exacerbations. A systematic review.

Valentin Prieto-Centurion, Michael A Markos, Norma I Ramey, Hélène A Gussin, Sharmilee M Nyenhuis, Min J Joo, Bharati Prasad, Nina Bracken, Robert Didomenico, Patrick O Godwin, Howard A Jaffe, Ravi Kalhan, Alan S Pickard, Barry R Pittendrigh, Bruce Schatz, Jamie L Sullivan, Byron M Thomashow, Mark V Williams, Jerry A Krishnan,

<h4>Rationale</h4>Approximately 20% of patients hospitalized for COPD exacerbations in the United States will be readmitted within 30 days. The Centers for Medicare and Medicaid Services has recently proposed to revise the Hospital Readmissions Reduction Program to financially penalize hospitals with high all-cause 30-day rehospitalization rates after a hospitalization for COPD ... Read more >>

Ann Am Thorac Soc (Annals of the American Thoracic Society)
[2014, 11(3):417-424]

Cited: 52 times

View full text PDF listing >>



Emerging Therapies for Acute and Chronic Heart Failure: Hope or Hype?

Sarah Hanigan, Robert J DiDomenico,

Although the period from 1953 to 2001 resulted in the approval of more than 30 medications currently used to treat heart failure (HF), few novel drugs have been approved in the last decade. However, the investigational pipeline for HF medications once again appears promising. In patients with chronic heart failure ... Read more >>

J Pharm Pract (Journal of pharmacy practice)
[2016, 29(1):46-57]

Cited: 2 times

View full text PDF listing >>



Engaging Patients and Caregivers to Design Transitional Care Management Services at a Minority Serving Institution.

Iulia D Ursan, Jerry A Krishnan, A Simon Pickard, Elizabeth Calhoun, Robert DiDomenico, Valentin Prieto-Centurion, Jamie B Sullivan, Lauren Valentino, Mark V Williams, Min Joo,

Limited socioeconomic resources contribute to high readmission rates at minority serving institutions (MSIs). A better understanding of patient-level factors and need for patient navigators could inform approaches to enhance care transitions tailored to these vulnerable patient populations. We sought to understand the perspectives of patients and their caregivers about hospital ... Read more >>

J Health Care Poor Underserved (Journal of health care for the poor and underserved)
[2016, 27(1):352-365]

Cited: 7 times

View full text PDF listing >>



The effect of cardiovascular credentialed pharmacists on process measures and outcomes in myocardial infarction and heart failure.

Michael P Dorsch, Jennifer M Lose, Robert J DiDomenico,

<h4>Objective</h4>The purpose of this study was to determine if institutions with inpatient cardiovascular credentialed pharmacists exhibit improved quality measures for acute myocardial infarction (AMI) and heart failure (HF) care compared with institutions without inpatient cardiovascular credentialed pharmacists.<h4>Methods</h4>We conducted a multicenter, retrospective, cross-sectional, matched case-control study. Hospitals with at least one ... Read more >>

Pharmacotherapy (Pharmacotherapy)
[2014, 34(8):803-808]

Cited: 7 times

View full text PDF listing >>



Comparison of practice patterns between inpatient cardiology pharmacists with and without added qualifications in cardiology.

Jennifer Lose, Michael P Dorsch, Robert J DiDomenico,

There is a paucity of data comparing practice patterns between board-certified specialists with added qualifications in cardiology (AQCV) and cardiovascular pharmacists without these credentials.The purpose is to characterize differences in practice between inpatient pharmacists with and without AQCV.We conducted a multicenter, retrospective, cross-sectional, case-controlled survey. An AQCV pharmacist list was ... Read more >>

Hosp Pharm (Hospital pharmacy)
[2015, 50(1):51-58]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.0345 s